Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 1999-11-22 | Forward | 2:1 |
| 1999-03-01 | Forward | 2:1 |
| 1995-08-16 | Forward | 2:1 |
| 1991-09-11 | Forward | 3:1 |
| 1990-08-13 | Forward | 2:1 |
Amgen Inc. is a global biotech company that develops and markets human therapeutics across areas like oncology, inflammation, and cardiovascular disease, partnering with various firms to innovate and distribute a broad portfolio of medicines.

Uplizna, a monoclonal antibody approved in 2025-2026 for generalized myasthenia gravis, marks a significant advancement in autoimmune treatment and reflects Amgen's focus on inflammation and rare diseases.
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
MRK | $145.31 | COMPARE |
NVS | $139.56 | COMPARE |
NVO | $43.47 | COMPARE |
GILD | $145.15 | COMPARE |
PFE | $27.74 | COMPARE |
DHR | $202.74 | COMPARE |
BMY | $64.03 | COMPARE |
SNY | $43.43 | COMPARE |